IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
The main purpose of this study is to assess the efficacy and safety of IBI310 in combination with sintilimab in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) locally advance or metastatic colorectal cancer.
Colorectal Cancer
BIOLOGICAL: IBI310 (anti-CTLA-4 antibody)|BIOLOGICAL: Sintilimab(anti-PD-1 antibody)
ORR, Objective Response Rate (ORR) in all MSI-H CRC patients as determined by independent review committee, Up to 3 years
ORR in all MSI-H CRC patients based on investigator assessment., Up to 3 years|Progression-Free Survival (PFS) both by investigator and IRC, Up to 3 years|Disease Control Rate (DCR) both by investigator and IRC, Up to 3 years|Duration of Response (DoR) both by investigator and IRC, Up to 3 years|Time To Response (TTR) both by investigator and IRC, Up to 3 years|Overall Survival, Up to 3 years|Incidence of adverse events (AE), Up to 3 years
The main purpose of this study is to assess the efficacy and safety of IBI310 in combination with sintilimab in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) locally advance or metastatic colorectal cancer.